EMN 2021 | Carfilzomib, lenalidomide and dexamethasone for lenalidomide-refractory myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the results of a retrospective observational analysis evaluating the efficacy and safety of carfilzomib in combination with lenalidomide and dexamethasone (KRD) as a salvage therapy for patients with lenalidomide-refractory multiple myeloma. 41 patients with relapsed/refractory multiple myeloma were included in the analysis. At a median follow-up of nine months, an overall response rate of 68.3% was observed, with nine complete responses and 12 very good partial responses. Eight patients achieved stable disease. The median overall survival from the start of carfilzomib therapy was 11 months. This interview took place during the 2021 European Myeloma Network (EMN) congress.
